Continuous Sternal Block
DeviceElastomeric Pump for Continuous Infusion of Local Anesthetic
Other names: ON-Q, PainBuster
NCT Number: NCT00673712
The main goals of the study are as follows: (1) to determine the correlation between pain management using continuous infusion of local anesthetics and the incidence of pneumonia and surgical infection in cardiac surgery patients; and (2) to evaluate the relationship between hospital-acquired pneumonia and surgical infection and patient outcomes, including length of hospital stay.
Looking for future studies?
Notify Me18 year and older
All sexes
Interventional
Phase 4
St. Vincents East, Birmingham, Alabama, United States
Nosocomial infections are recognized as an important cause of increased patient morbidity and mortality. The reported prevalence for nosocomial infections most commonly ranges from 5 to 20%, but can be significantly greater among patients requiring intensive care. The most common sites of hospital acquired infection include the lung, urinary tract, surgical wounds, and the bloodstream. Patients undergoing cardiac surgery appear to be at increased risk for the development of nosocomial infections due to the presence of multiple surgical wounds (chest and lower extremity incisions), frequent postoperative utilization of invasive devices (i.e. central venous catheters, chest drains, intra-aortic balloon counter pulsation, pulmonary artery catheter), and the common use of prophylactic or empiric antibiotics in the perioperative period. In the cardiac surgical postoperative period, nosocomial infections have been found to be associated with prolonged length of stay (LOS) in the ICU and total hospitalization, development of multiorgan dysfunction, and increased hospital mortality. Nosocomial Pneumonia (NP) is in fact the leading cause of mortality due to hospital-acquired infections. Patients with Ventilator Associated Pneumonia (VAP) have been found in various studies to have significantly higher mortality rates than those without VAP, with ranges of 20.2-45.5% and 8.5-32.2%, respectively. Strategies that both reduce postoperative pain and sedation have the potential to reduce postoperative pneumonia by allowing earlier extubation and more effective pulmonary toilet post-extubation. Non-opioid pain management has the potential to reduce NP rates because of superior pain management, as well as the reduction in opioids required, and the concomitant avoidance of opioid side effects. The clinical and financial consequences of NP justify aggressively pursuing strategies aimed at prevention. Specifically, these strategies are targeted at reducing the incidence of NP by addressing the modifiable risk factors including prolonged endotracheal intubation and ventilator support, sedation, and long hospital LOS.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Elastomeric Pump for Continuous Infusion of Local Anesthetic
Other names: ON-Q, PainBuster
Opioid Analgesic agents delivered by:
PCA on demand mode IV injections PRN IM injections PRN Oral PRN
Other names: PCA
Time frame: 30 days postoperative
Pneumonia diagnosed during hospitalization
Time frame: 30 days postoperative
surgical site infection diagnosed within 30 days post surgery
Time frame: primary admission
time (days) from date of admission to discharge
Halyard Health
Industry
Phase 4 Multicenter Infection Surveillance Study Following Cardiac Surgical Procedures
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT05919888
Cutibacterium Acnes, Infections
St Louis, Missouri, United States
View Trial DetailsNCT03598413
Atrophy, Colonic Diseases
Guildford, Surrey, United Kingdom
View Trial DetailsNCT04735133
Colonic Diseases, Colorectal Cancer
Kayseri, Melikgazi, Turkey (Türkiye)
View Trial DetailsNCT03462524
Adenocarcinoma, Carcinoma
Dublin, Ireland
View Trial Details